As the UK officially left the EU at the end of last month, Brexit is now well underway. The country is currently in the midst of an 11-month transition period, during which the government will [...]
In recent years, there has been increased recognition of the important role that patients can play in enhancing drug development and approval efforts. Because patients are experts in their disease area, they can provide useful [...]
Although the UK is home to some of the world’s leading scientific and medical researchers, the country has historically struggled to make effective use of large-scale patient health data. In an effort to combat this, [...]
The Orphan Drug Act (ODA), which was passed in 1983 to incentivize drug development for rare diseases, has come under scrutiny in recent years. There are some within industry who claim that the program has been [...]
In the last remaining months leading up to the UK’s exit from the EU, the Medicines and Healthcare products Regulatory Agency (MHRA) is taking action to prepare for a potential ‘no-deal’ Brexit. The MHRA strongly [...]
With the Brexit leave date fast approaching, efforts are continuously being made to ensure that patient health and wellbeing remain protected, following the UK’s exit from the EU. Last month, the Secretary of State for [...]
Medicine shortages and rising drug prices continue to plague the US healthcare system, despite efforts being made by government on the national and local level to combat the issue. As it stands, hospitals around the [...]
In a move that defies President Trump’s proposed budget for fiscal 2019, the Senate is gearing up to approve a $2 billion increase in funding for the National Institutes of Health (NIH). This increase has [...]
Late last month, The National Organization for Rare Disorders (NORD) launched its new initiative, RareInsights, aimed at expanding public knowledge of rare diseases and using that knowledge to create real-world solutions for patients. NORD is [...]
Last week, President Trump’s administration released its new drug pricing plan, which calls for more competition and negotiation as well as greater incentives to lower list prices and out-of-pocket costs for patients. However, many commentators [...]